Abstract

ROLE OF INTERNATIONAL PRODUCT OF SIMVASTATIN ON LIVER FUNCTION TEST IN PATIENTS WITH PRIMARY DYSLIPIDEMIA

Naveed Ali Siddiqui*, Shanila Feroz, Jai Kershan, Kiran, Rabyyan Junaid, Mohammad Yahya and Saba Fatima

ABSTRACT

Objective: To observe the changes in liver function test in patients with primary dyslipidemia using international lipid lowering drug, Simvastatin. Material and Methods: This clinical trial was carried out at Surgeon Munawar Memorial Hospital, Karachi. The study was designed to assess the effects of HMG-CoA reductase inhibitor (Simvastatin) on LFT in patients with primary dysplipidemia. The study period consists of 8 weeks from 4th April 2016 to 29th May 2016. The exclusion included lactating/pregnant women’s, renal, liver and established coronary artery disease. Results: Thirty patients with abnormal lipid profile were included in the study (age 30-60 years). Patients were orally administered with international product of Simvastatin (20mg/day) for 8 weeks. The total bilirubin, direct bilirubin, ALT, AST, alkaline phosphatase was estimated in the serum of primary dyslipidemic patients before and after treatment with international product of Simvastatin (20mg/day). After the treatment serum total bilirubin, direct bilirubin, ALT, AST, alkaline phosphatase were increased. Conclusion: On the basis of this study it is concluded that Simvastatin increases the level of total bilirubin, direct bilirubin, ALT, AST and alkaline phosphatase.

Keywords: LFT, Dysplipidemia, Simvastatin.